Our data may also suggest that pharmacological modulation of serotonin system could be used to modulate insulin secretion or reduce IR in women with PCOS in particular when depressive symptomatology is accompanied that is common in these patients and presumably also in other conditions with metabolic disorders associated with IR and depressive symptomatology at the same time. This evidence concerns the gene INS and metabolic disease.